Fig. 1 · Structure

Documents & Downloads

Bindarit

Cat. No. A11821 CAS 130641-38-2

MCP inhibitor

Bindarit is an anti-inflammatory small molecule that modulates the NFκB pathway.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
MCP-1/CCL2
MCP-3/CCL7
MCP-2/CCL8

Bindarit Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Bindarit from 3 published references. In vitro models include MM-6 cells; microglia, prepared from C57BL/6 mouse brain.

Bindarit In Vitro Studies

In MM-6 cells, Bindarit inhibited MCP-1 with an IC50 of 250 ± 60 μM and did not change basal cytokine expression in unstimulated cells. In mouse brain-derived microglia, Bindarit at 50 μM for 4 hr reduced basal CCL2 mRNA by nearly 75%. In rat VSMCs, Bindarit at 100 and 300 µM significantly inhibited PDGF-BB-induced proliferation by 27% and 42%, respectively, compared with PDGF-BB controls. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Bindarit inhibits release of MCP-1 from LPS-stimulated MM-6 cells

Cell-based study · MM-6 cells [1]

In preliminary experiments, the IC50 of bindarit was 250 ± 60 μM. In unstimulated cells, bindarit alone did not change the basal expression of the two cytokines.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
inhibition of MCP-1IC50 IC50 of bindarit was 250 ± 60 μM[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Bindarit

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Bindarit differentially regulates LPS-mediated secretion of IL-8 and MCP-1 (S2, S3, S5)

inhibition of MCP-1: inhibition of MCP-1 — Results > Bindarit differentially regulates LPS-mediated secretion of IL-8 and MCP-1 (S3, S5)

Bindarit suppresses basal CCL2 expression in mouse microglia

Cell-based study · Microglia, prepared from C57BL/6 mouse brain [2]

Microglia prepared from C57BL/6 mouse brain were incubated with Bindarit at 50 μM for 4 hr. Basal CCL2 mRNA was reduced by nearly 75%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative CCL2 RNA levels were determined by qRT-PCRCCL2 mRNA nearly 75% reduction[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
4 hr
Method
incubated with bindarit
Vehicle
dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: Bindarit

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Preparation of bindarit (S4); Results > Bindarit differentially suppresses CCL2 expression by cultured CNS cells (S75); Figure 1 legend (S117, S118, S119)

Relative CCL2 RNA levels were determined by qRT-PCR: Relative CCL2 RNA levels were determined by qRT-PCR; comparator: Control cultures received only vehicle. — Results > Bindarit differentially suppresses CCL2 expression by cultured CNS cells (S75); Figure 1 legend (S119)

Bindarit inhibits PDGF-BB-induced rat vascular smooth muscle cell proliferation

Cell-based study · rat VSMCs [3]

Rat VSMCs were incubated with Bindarit in medium containing PDGF-BB. Bindarit at 100 and 300 µM significantly inhibited PDGF-BB-induced proliferation by 27% and 42%, respectively, compared with PDGF-BB alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell proliferation assayVSMCs proliferation 27% and 42%[3]

Literature-Reported Treatment Conditions

Treatment concentration
10–300 µM
Exposure duration
48 h
Method
incubated with DMEM containing PDGF-BB
Co-treatment
Other interventions in this design: PDGF-BB 10 ng/mL. Compound effect isolated by the comparison: vs. platelet derived growth factor-BB (PDGF-BB).
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Bindarit

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Enzyme-linked immunosorbent assay for MCP-1 protein (S10); Methods > Proliferation assay (S12, S13); Methods > Chemotactic migration and invasion (S18); Results > Effect of bindarit on rat VSMC proliferation and migration (S83); Figure 1 legend (S127)

cell proliferation assay: cell proliferation assay; comparator: PDGF-BB — Methods > Proliferation assay (S12); Results > Effect of bindarit on rat VSMC proliferation and migration (S83)

Bindarit In Vivo Studies

Male Wistar rats with carotid arterial injury received Bindarit orally by gastric gavage at 100 mg/kg twice a day. Bindarit significantly inhibited neointima formation by 39% compared with control animals. [3]

Inhibition of Neointima Formation Following Carotid Arterial Injury

Animal study · Male Wistar rats; rat carotid arterial injury model [3]

Male Wistar rats with carotid arterial injury received Bindarit orally by gastric gavage at 100 mg/kg twice a day. Bindarit significantly inhibited neointima formation by 39% compared with control animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
neointima formationneointima formation 200 mg/kg/day: inhibition of neointima formation by 39% at day 14[3]

Conditions shared by the study groups

Route
given orally, by gastric gavage
Treatment course
twice a day; from 2 days before angioplasty up to 14 days after
Vehicle
0.5% methylcellulose aqueous solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bindarit 100 mg/kgcontrol animals received an equal volume of methylcellulose (0.5 mL/100 g in rats; 0.1 mL/10 g in mice)Bindarit caused a significant inhibition of neointima formation by 39% (P < 0.01, n = 19) at day 14 compared with the control animals[3]
Bindarit 100 mg/kg
Model: Male Wistar rats; rat carotid arterial injury model
Methods and source locations

Compound reported in the paper: Bindarit

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Treatments (S3, S4); Methods > Animals (S22); Methods > Rat carotid balloon angioplasty (S25); Methods > Evaluation of neointima formation (S33); Results > Effect of bindarit on neointima formation in rat carotid arteries (S93, S95); Figure 2 legend (S130)

neointima formation: neointima formation; comparator: control animals received an equal volume of methylcellulose (0.5 mL/100 g in rats; 0.1 mL/10 g in mice) — Results > Effect of bindarit on neointima formation in rat carotid arteries (S95); Figure 2 legend (S130)

Bindarit 100 mg/kg · Methods > Treatments (S3); Results > Effect of bindarit on neointima formation in rat carotid arteries (S95)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 130641-38-2
Applications MCP inhibitor
Formula C19H20N2O3
Molecular Weight 324.37
SMILES
CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 61 mg/mL (188.05 mM)
Water Insoluble
Ethanol 61 mg/mL (188.05 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
6 mg/mL
Vehicle
0.5% CMC

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bindarit Research References

  1. [1] Oddi S, Scipioni L, Totaro A, et al. The anti-inflammatory agent bindarit acts as a modulator of fatty acid-binding protein 4 in human monocytic cells. Sci Rep (2019). PMID: 31641194 DOI: 10.1038/s41598-019-51691-y Source material
  2. [2] Ge S, Shrestha B, Paul D, et al. The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis. J Neuroinflammation (2012). PMID: 22788993 DOI: 10.1186/1742-2094-9-171 Source material
  3. [3] Grassia G, Maddaluno M, Guglielmotti A, et al. The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res (2009). PMID: 19592568 DOI: 10.1093/cvr/cvp238 Source material

Added to your cart

View Cart Checkout
Loading...